723280-94-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromo-4-hydroxy-3-nitroquinoline is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs and medications.
Used in Antimicrobial Applications:
7-Bromo-4-hydroxy-3-nitroquinoline is studied for its potential antimicrobial properties. It can be used as an antimicrobial agent to combat various types of bacteria, helping to treat infections and prevent the spread of diseases.
Used in Antiviral Applications:
7-BroMo-4-hydroxy-3-nitroquinoline has also been investigated for its potential antiviral properties. It can be used as an antiviral agent to inhibit the replication of viruses, providing a potential treatment for viral infections.
Used in Antifungal Applications:
7-Bromo-4-hydroxy-3-nitroquinoline is studied for its potential antifungal properties. It can be used as an antifungal agent to treat fungal infections and prevent the growth of fungi in various settings.
Used in Chemical and Biological Research:
7-Bromo-4-hydroxy-3-nitroquinoline has been investigated for its potential use as a fluorescent probe in chemical and biological research. Its fluorescent properties allow it to be used in various experimental techniques, such as fluorescence microscopy and spectroscopy, to study biological processes and interactions at the molecular level.

Upstream product

• 82121-06-0 4-hydroxy-7-bromoquinoline 

Downstream Products

• 1232149-36-8 4-amino-7-bromo-3-nitroquinoline 
• 1232149-37-9 7-bromo-3,4-diaminoquinoline 
• 723280-98-6 7-bromo-4-chloro-3-nitroquinoline 

Relevant academic research and scientific papers

NLRP3 MODULATORS

The present invention provides compounds of Formula (I), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

IMMUNOCONJUGATES TARGETING PD-L1

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

IMMUNOCONJUGATES TARGETING CEA

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen ("CEA") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF

The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention o

IMMUNOCONJUGATES TARGETING HER2

The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 ("HER2") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

MACROMOLECULE-SUPPORTED TLR AGONISTS

The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule- supported compounds.

IMMUNOCONJUGATES

The invention provides an immunoconjugate comprising (a) an antibody construct comprising (i) an antigen binding domain and (ii) an Fc domain and (b) 1-8 adjuvant cores, wherein each adjuvant core is covalently bonded to the antibody construct via a linker, wherein each adjuvant core comprises a 2-amino nitrogen moiety with a pendant nitrogen atom and a point of attachment of the linker to the adjuvant core, and wherein the distance between the pendant nitrogen atom and the point of attachment of the linker is greater than about 5 ?. The invention also provides methods for treating cancer with the immunoconjugates.

SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/ or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

NLRP3 MODULATORS

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS

Thiazolo[4,5-c] ring compounds, (e.g. thiazolopyridine, thiazoloquinoline, 6,7,8,9-tetrahydrothiazoloquinoline, thiazolonaphthyridine, and 6,7,8,9-tetrahydrothiazolonaphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, p